MoneyWorks4Me

SMS Pharmaceuticals - Quaterly Results

09 Nov 2025 Evaluate
The Revenue for the quarter ended  September 2025 of Rs. 2424.30 millions grew by 23.22 % from Rs. 1967.48 millions.Profit for the quarter ended September 2025 rises by 76.36% to Rs. 251.44  millions from Rs. 142.57 millions.Operating Profit saw a handsome growth to 498.13 millions from 331.65 millions in the quarter ended September 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202509 202409 % Var 202509 202409 % Var 202503 202403 % Var
Sales 2424.30 1967.48 23.22 4384.77 3611.99 21.39 7827.48 7092.63 10.36
Other Income 14.34 13.05 9.89 20.27 26.73 -24.17 62.24 44.60 39.55
PBIDT 498.13 331.65 50.20 892.67 679.98 31.28 1461.98 1213.04 20.52
Interest 57.36 46.06 24.53 115.76 92.73 24.84 185.41 234.57 -20.96
PBDT 440.77 285.59 54.34 776.91 587.25 32.30 1276.57 978.47 30.47
Depreciation 100.21 86.20 16.25 197.73 170.02 16.30 343.37 315.16 8.95
PBT 340.56 199.39 70.80 579.18 417.23 38.82 933.20 663.31 40.69
TAX 89.12 56.82 56.85 145.66 111.38 30.78 249.39 169.07 47.51
Deferred Tax 6.62 9.82 -32.59 13.16 11.38 15.64 52.99 17.79 197.86
PAT 251.44 142.57 76.36 433.52 305.85 41.74 683.81 494.24 38.36
Equity 93.65 84.65 10.63 93.65 84.65 10.63 88.65 84.65 4.73
PBIDTM(%) 20.55 16.86 21.90 20.36 18.83 8.14 18.68 17.10 9.21
Peers
Company Name CMP
Sun Pharma. Inds. 1835.50
Dr. Reddys Labs. 1171.10
Cipla 1371.45
Lupin 2144.70
Zydus Lifesciences 1153.00
View more..